— Know what they know.
Not Investment Advice

NAYA NASDAQ

NAYA Biosciences, Inc.
1W: -9.2% 1M: -7.3% 3M: -61.0% 1Y: -84.0% 3Y: -99.5%
$2.20
Last traded 2025-05-22 — delisted
NASDAQ · Healthcare · Medical - Devices · $1.5M mcap · 336490 float · 463.72% daily turnover · Short 42% of daily vol

Balance Sheet Trends

Total Assets
$46M +151.0% ▲
5Y CAGR: +91.7%
Total Liabilities
$34M +91.3% ▲
5Y CAGR: +43.7%
Shareholders Equity
$13M +1327.8% ▲
Cash & Investments
$741K +219.0% ▲
5Y CAGR: -9.8%
Total Debt
$10M +57.0% ▲
5Y CAGR: +84.9%
Net Debt
$9M +50.8% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$10M$6M$90K$232K$741K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$10M$6M$90K$232K$741K
Net Receivables$22K$50K$77K$141K$175K
Inventory$265K$288K$264K$265K$220K
Other Current Assets$0$0$190K$622K$182K
Total Current Assets$11M$6M$621K$1M$1M
Property, Plant & Equip.$212K$3M$2M$4M$3M
Goodwill & Intangibles$95K$132K$0$10M$42M
Long-Term Investments$98K$1M$1M$3M$741K
Other Non-Current Assets$240$0$0$0$0
Total Non-Current Assets$405K$4M$3M$17M$45M
Total Assets$11M$10M$4M$19M$46M
— Liabilities —
Accounts Payable$329K$443K$1M$2M$6M
Short-Term Debt$694K$0$763K$2M$6M
Deferred Revenue$714K$6K$120K$409K$602K
Other Current Liabilities$527K$582K$946K$1M$3M
Total Current Liabilities$2M$1M$3M$8M$18M
Long-Term Debt$0$0$0$1M$1M
Other Non-Current Liab.$0$0$0$5M$12M
Total Non-Current Liabilities$3M$2M$1M$10M$16M
Total Liabilities$5M$3M$5M$18M$34M
— Equity —
Common Stock$964$1K$61$249$37
Retained Earnings-$32M-$39M-$50M-$58M-$67M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$6M$7M-$978K$893K$13M
Total Liabilities & Equity$11M$10M$4M$19M$46M
— Key Metrics —
Total Debt$775K$2M$2M$6M$10M
Net Debt-$9M-$4M$2M$6M$9M
Total Investments$98K$1M$1M$3M$741K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms